Low-dose anti-IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance

Mepolizumab at the dose of 300 mg/4 weeks has been recently approved as an add-on therapy for patients with uncontrolled hypereosinophilic syndrome (HES) without any identifiable non-hematologic secondary cause. According to the available real-life evidence mepolizumab 300 mg and 100 mg, licensed fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Caminati, Marco, Maule, Matteo, Benoni, Roberto, Micheletto, Claudio, Tecchio, Cristina, Vaia, Rachele, De Franceschi, Lucia, Guarnieri, Gabriella, Vianello, Andrea, Senna, Gianenrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521477/
https://www.ncbi.nlm.nih.gov/pubmed/37752586
http://dx.doi.org/10.1186/s13023-023-02918-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521477/
https://www.ncbi.nlm.nih.gov/pubmed/37752586
http://dx.doi.org/10.1186/s13023-023-02918-9

Ejemplares similares